Is IBRX a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for ImmunityBio (IBRX) rests on Anktiva revenue ramp: Net product revenue grew roughly 700% in full-year 2025 to about $113 million, then climbed each quarter in 2026: about $44 million in the first quarter and about $51 million in the second, up roughly 94% year over year. The bear case rests on iBRX carries the full risk profile of an unprofitable commercial-stage biotech. Analysts covering it publish targets from $12.00 to $16.00 against a $9.18 price, so even the professionals disagree by 28% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy. Its approved use is in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The original April 2024 approval covered carcinoma in situ (CIS); on October 14, 2026 the FDA expanded the label to include patients whose tumors are papillary-only, which the company says is the first FDA approval for that group. Papillary disease accounts for roughly 85% of the NMIBC population by the company's figures, so the change widens the eligible pool considerably. The company is also pushing label expansions into BCG-naive bladder cancer and lung cancer while building out global commercial partnerships across roughly 33 to 34 countries. The founder and largest shareholder, Patrick Soon-Shiong, remains central to the story and its strategy. The investment picture is a classic early-commercial biotech: revenue is growing very quickly but from a small base, the company is still deeply unprofitable, and it burns cash each quarter, which has historically been funded through equity and financing that dilutes existing holders. Second-quarter 2026 revenue was about $51 million, up roughly 94% year over year, and trailing twelve-month revenue reached about $166 million, but the quarter's loss of $0.22 per share was well wider than the roughly $0.08 analysts expected. As of October 16, 2026 the stock closed at $9.42, up about 366% year to date and 272% over twelve months, for a market value near $10 billion, roughly 60 times trailing sales. That combination of approved-product traction plus a big valuation on small sales makes IBRX a high-variance name whose outcome hinges on execution, regulatory decisions, and access to capital. Third-quarter results are expected around November 3.

The bull case: what would have to be true for $16.00

The most optimistic published target on IBRX is $16.00, +74.3% from the $9.18 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Anktiva revenue ramp

Net product revenue grew roughly 700% in full-year 2025 to about $113 million, then climbed each quarter in 2026: about $44 million in the first quarter and about $51 million in the second, up roughly 94% year over year. Analysts expect about $59 million for the September quarter and roughly $227 million for full-year 2026, rising to about $472 million in 2027. Continued physician uptake in BCG-unresponsive NMIBC is the core near-term growth engine, and the base is still small enough that percentage growth can stay high while absolute dollars remain modest.

2. Label and indication expansion

The October 14, 2026 approval extending Anktiva to papillary-only BCG-unresponsive NMIBC is the first expansion to land, and it arrived ahead of the scheduled review date. ImmunityBio is also pursuing BCG-naive NMIBC, with a late-stage registrational trial reported as fully enrolled and an sBLA submission targeted for 2026, plus early data in lung cancer. Each additional approved use widens the addressable population, and these expansions are the main justification for the current valuation, so timing and outcomes matter a great deal.

3. Global commercial partnerships

The company has signed distribution and approval arrangements spanning roughly 33 to 34 countries across multiple regulatory jurisdictions. International approvals can add revenue without ImmunityBio bearing the full commercial cost. Execution across many geographies and partners adds complexity and uncertainty.

4. Broader immunotherapy pipeline

Beyond Anktiva monotherapy combinations, ImmunityBio is exploring NK-cell therapy and other immunotherapy combinations across solid tumors. A wider pipeline offers optionality if additional programs advance. Most of these remain early and unproven, so they are potential upside rather than current value.

The bear case: what would have to be true for $12.00

The most pessimistic published target is $12.00, +30.7% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks ImmunityBio is worth if the risks below bite instead of the drivers above.

IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses in 2026 (about $633 million in the first quarter and $230 million in the second, inflated by non-cash items), and trailing twelve-month operating cash outflow was about $281 million, or roughly $70 million a quarter, which repeatedly requires financing that can dilute existing shareholders. Cash stood near $357 million at June 30, 2026 against about $1.23 billion of debt. The second-quarter loss per share ($0.22) was far wider than the roughly $0.08 consensus, a reminder that the path to breakeven is not smooth. Its market value (about $10 billion) is roughly 60 times trailing revenue of about $166 million, and the stock has already risen more than fourfold in 2026, so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding IBRX already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on IBRX

4 analysts cover IBRX, with an average target of $14.25 (+55.2% against $9.18) and a split of 4 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the IBRX forecast and price target page.

How is IBRX valued? (as of October 2026)

Price

$9.18

Market cap

$9.73B

Forward P/E

-57.38

Beta

0.03

52-week range

$1.95 to $12.43

Snapshot for IBRX as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$166M
Revenue growth (Q2 2026 YoY): ~94%
Q2 2026 revenue: ~$51M
Net loss (TTM): ~$992M (EPS ~-$0.96)
Cash and debt (Jun 30, 2026): ~$357M cash, ~$1.23B debt
Operating cash flow (TTM): ~-$281M (~$70M a quarter)
Market capitalization: ~$10.0B (~60x TTM sales)

The valuation is striking: a roughly $10 billion market value against about $166 million of trailing revenue is a price-to-sales multiple near 60, and it prices in the 2027 consensus of roughly $472 million of revenue and beyond. The company is not profitable, analysts still expect a loss of about $0.16 per share in 2027, and it funds ongoing losses partly through financing, so cash runway and dilution are central to the story. These figures are as of October 2026 and shift with each quarterly report and any capital raise.

How do you decide if IBRX is a buy?

Rather than asking whether IBRX is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold IBRX indirectly through an index or sector ETF before adding more.

What would change your mind on IBRX

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Anktiva revenue ramp stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: iBRX carries the full risk profile of an unprofitable commercial-stage biotech fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the IBRX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IBRX against your real portfolio and see your actual exposure before deciding.

Investing in ImmunityBio with AI

Connect the broker you already use and ask Walnut's AI how IBRX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does IBRX fit me?

FAQ

Is IBRX a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Anktiva revenue ramp, with revenue (ttm) at ~$166M. The bear case rests on iBRX carries the full risk profile of an unprofitable commercial-stage biotech. Analysts covering it are spread from $12.00 to $16.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell IBRX?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. IBRX carries the full risk profile of an unprofitable commercial-stage biotech. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $12.00, +30.7% from the $9.18 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for IBRX?

Anktiva revenue ramp. Net product revenue grew roughly 700% in full-year 2025 to about $113 million, then climbed each quarter in 2026: about $44 million in the first quarter and about $51 million in the second, up roughly 94% year over year. The most optimistic analyst target on IBRX is $16.00, +74.3% from the $9.18 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for IBRX?

What does ImmunityBio do?

ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy.

What would have to change for IBRX to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Anktiva revenue ramp) stalling in the reported numbers rather than in the narrative, the risk above (iBRX carries the full risk profile of an unprofitable commercial-stage biotech) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does ImmunityBio (IBRX) do?

ImmunityBio is a commercial-stage immunotherapy company. Its lead product, Anktiva, is an FDA-approved IL-15 receptor agonist immunotherapy used with BCG for BCG-unresponsive non-muscle invasive bladder cancer, now covering both carcinoma in situ and papillary-only disease after an October 2026 label expansion, and the company is pursuing additional cancer indications.

Is IBRX profitable?

No. As of October 2026 ImmunityBio is unprofitable, with a trailing twelve-month net loss of about $992 million (much of it non-cash) while it invests in commercialization and trials. Operating cash outflow runs roughly $70 million a quarter, which it has funded partly through financing that can dilute shareholders.

How fast is Anktiva revenue growing?

Very fast off a small base. Full-year 2025 net product revenue rose about 700% to roughly $113 million, first-quarter 2026 revenue was about $44 million, and second-quarter revenue reached about $51 million, up roughly 94% year over year. High percentage growth reflects the early stage of the launch.

Walnut is informational, not investment advice, and gives no verdict on IBRX. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.